CTOs on the Move


 
Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Brightseed raised $27M on 09/15/2020
Brightseed raised $68M on 05/09/2022

Similar Companies

Allyis Inc

Allyis Inc is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Target RWE Health Evidence Solutions

At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

Protagonist Therapeutics

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.

AbSci

AbSci is a global leader in biomanufacturing technologies. The company`s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes.